评论 9
过滤器:
评分
语言
种类:
最近的
B
8 几个月前

I want to express my gratitude for the exceptional...

I want to express my gratitude for the exceptional service provided by Dewpoint Therapeutics. Their team was highly professional and efficient. They were able to solve our problem in a timely manner. I highly recommend their services.

S
10 几个月前

I had a positive experience with Dewpoint Therapeu...

I had a positive experience with Dewpoint Therapeutics. The quality of their work was good and the results were satisfactory. I would consider using their services again in the future.

C
1年以前

I had a great experience with Dewpoint Therapeutic...

I had a great experience with Dewpoint Therapeutics. Their team was very professional and knowledgeable. They provided excellent service and delivered results beyond my expectations. I highly recommend their services.

G
1年以前

The service I received from this company was outst...

The service I received from this company was outstanding. They were able to meet all my expectations and delivered the results on time. I would definitely use their services again in the future.

R
1年以前

I had an average experience with Dewpoint Therapeu...

I had an average experience with Dewpoint Therapeutics. While the service was adequate, I felt that there was room for improvement in terms of communication and timeliness. Overall, it was an okay experience.

S
1年以前

👍 I'm really impressed with the services provided ...

👍 I'm really impressed with the services provided by Dewpoint Therapeutics. They have a great team and their work is top-notch. I'm extremely satisfied with the results. Keep up the good work! 👍

关于Dewpoint therapeutics

露点疗法:将凝结物生物学转化为急需的药物

Dewpoint Therapeutics 是一家生物技术公司,专门从事将凝结生物学转化为急需的药物。该公司的使命是利用凝析油的力量为患有多种重要疾病的患者开发创新疗法。

凝聚物是动态的无膜细胞器,在细胞功能和疾病中起着至关重要的作用。它们是由细胞内的蛋白质、核酸和其他生物分子相分离形成的。冷凝物涉及许多重要的生物过程,包括基因表达、信号通路和应激反应。

Dewpoint Therapeutics 由 Mark Murcko 博士和 Amir Nashat 博士于 2019 年创立,目标是利用凝聚生物学的潜力为医疗需求未得到满足的患者开发新疗法。公司汇集了世界一流的科学家和药物开发人员团队,致力于推进这一激动人心的领域。

该公司的方法基于其称为“分子凝聚物”的专有平台技术。该技术使 Dewpoint 能够设计小分子,选择性地针对疾病过程中涉及的特定凝聚物。通过调节这些冷凝物,露点旨在恢复正常的细胞功能并减轻疾病症状。

Dewpoint 的产品线包括几种有前途的候选药物,针对癌症、阿尔茨海默病或帕金森病等神经退行性疾病以及 COVID-19 或流感病毒感染等病毒感染。

一个例子是他们的主要候选药物 DPT-1,它通过破坏由驱动白血病发展的突变 NPM1c 蛋白变体形成的病理核体 (PNB) 内的异常蛋白质-蛋白质相互作用来靶向 NPM1c 驱动的白血病——一种侵袭性血癌。

另一个例子是他们的项目通过破坏病毒复制细胞器 (RO) 的形成来靶向 SARS-CoV-2 病毒复制,这些细胞器是由病毒蛋白和宿主因子相分离形成的。该计划旨在开发一类新型抗病毒药物,可用于治疗 COVID-19 和其他新发传染病。

Dewpoint Therapeutics 还与领先的制药公司、学术机构和研究组织建立了多项战略合作伙伴关系。这些合作使 Dewpoint 能够利用其在凝聚物生物学和药物发现方面的专业知识来加速为患者开发新疗法。

总之,Dewpoint Therapeutics 是一家尖端生物技术公司,处于将凝聚物生物学转化为急需药物的前沿。凭借其创新的平台技术、世界一流的团队和战略合作伙伴关系,Dewpoint 处于有利地位,可以通过为患有各种重要疾病的患者开发新的治疗方法来对人类健康产生重大影响。

已翻译
Dewpoint therapeutics

Dewpoint therapeutics

4.1